EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

Yasuo Imanishi iD, Takumi Imai, Hisako Fujii, Rei Aida, Yuki Nagata, Tetsuo Shoji iD, Shinichiro Kashiwagi, Tsutomu Takashima, Masanori Emoto

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yasuo Imanishi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Risedronic Acid, Aromatase Inhibitors, Breast Neoplasms, Vitamin D. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co., Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR + EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.

Objective

To determine the effect of eldecalcitol (0.75 ug/day) add-on therapy to risedronate (17.5 mg/week) on bone quantity and quality in women treated with AI.

Design

Open-label randomized control trial.

Setting

Postmenopausal women with HR + EBC (TNM stage 0-3A) treated with risedronate for more than 12 months. Patients Two hundred patients were enrolled; 196 patients were eligible for the full analysis set after excluding those without follow-up BMD data. Participants were advised to take vitamin D and calcium, yet many were vitamin D deficient or insufficient.

Intervention

Participants were randomly assigned in a 1:1 ratio to receive either eldecalcitol add-on therapy or risedronate monotherapy. Main Outcome Measure The primary outcome was the group difference in the change of lumbar spine (LS)-BMD in 24 months. Secondary outcomes included femoral neck (FN)-BMD, total hip (TH)-BMD, trabecular bone score (TBS), and the incidence of vertebral and nonvertebral fractures.

Results

The increase at LS-, FN-, and TH-BMD at 24 months was larger in the add-on therapy group than in the monotherapy group, with a group difference (add-on therapy minus monotherapy) estimate of 0.020 g/cm2 [95% confidence interval (CI): 0.010-0.029 g/cm2, P < .001] for LS-BMD. The incidence rate ratio (add-on therapy/monotherapy) for morphometric vertebral fractures was 0.292 (95% CI: 0.080-1.061, P = .061). No group difference was detected in the change in TBS.

Conclusion

Eldecalcitol add-on therapy increased LS-BMD in osteopenic to osteoporotic postmenopausal women treated with an AI and risedronate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Risedronic AcidAromatase InhibitorsBreast NeoplasmsVitamin DBone Density Conservation AgentsOsteoporosis, PostmenopausalHumansFemaleAgedMiddle AgedBone DensityDrug Therapy, Combination

Stichwörter der Autor:innen

AIBLEBCTBSaromatase inhibitor-associated bone lossearly-stage breast cancereldecalcitolrisedronatetrabecular bone score

Substanzen

Risedronic AcidAromatase InhibitorseldecalcitolVitamin DBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Health and Medical Innovation, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Breast Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

ORCID-Profile: Yasuo Imanishi, Tetsuo Shoji

Förderung

  • Chugai Pharmaceutical Co., Limited

Zitieren

APA

Imanishi, Y., Imai, T., Fujii, H., Aida, R., Nagata, Y., Shoji, T., Kashiwagi, S., Takashima, T., & Emoto, M. (2025). Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf019

Vancouver

Imanishi Y, Imai T, Fujii H, Aida R, Nagata Y, Shoji T, et al. Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf019

BibTeX
@article{Imanishi2025,
  author = {Imanishi, Yasuo and Imai, Takumi and Fujii, Hisako and Aida, Rei and Nagata, Yuki and Shoji, Tetsuo and Kashiwagi, Shinichiro and Takashima, Tsutomu and Emoto, Masanori},
  title = {Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf019}
}
Kostenlos starten →